Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.
Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove to be problematic for the biotech giant going forward.